Press Releases

Five years ago my namefellow, Andrew A. Radin (twoXAR CEO), and I launched twoXAR to apply new technology to discovering medicines for patients with unmet medical needs. Over the years we developed our 3P strategy (platform, process, portfolio) which I am confident is the most efficient, lowest risk, and highest probability path to success in today’s world of drug development.

After careful consideration and planning I’ve decided now is the right time for me to transition to an advisory role at twoXAR. To implement the 3P strategy we’ve built an exceptional team of scientists, engineers, and business professionals that continues to develop and broaden month over month. I am consistently impressed by our team’s expertise, capabilities, and accomplishments — it’s their commitment and dedication that propels forward our mission... read post here.

This week I had the pleasure to sign an R&D collaboration agreement with SK Biopharmaceuticals, our new friends at in South Korea’s Pangyo Techno Valley.

In the last several months, SKBP has achieved several remarkable drug development milestones, including the first FDA approval of an SKBP-discovered drug (Sunosi™, for excessive daytime sleepiness associated with narcolepsy or obstructive sleep apnea, which has been licensed to Jazz Pharmaceuticals) and FDA acceptance of their NDA submission for cenobamate, an investigational antiepileptic drug. With this recent progress, SKBP is quickly emerging as the leading end-to-end pharmaceutical company in South Korea... read post here.

I'm pleased to announce that we have signed our second partnership deal of 2019; this time in a (undisclosed) neurological disease with Ono Pharmaceutical.

Ono recently celebrated their 300th anniversary of delivering medications to patients in need. When I visited their research headquarters in Osaka, Japan I was impressed by the exposition in their lobby chronicling their rich history. I was reminded of the evolution of the industry and of twoXAR itself... read post here.

Having devoted my professional life to the discovery and development of novel therapies to tackle life-threatening diseases, including drug-resistant forms of cancer, I am thrilled to be working with an innovative discovery approach for the treatment of glioblastoma.

Glioblastoma multiforme is the most common and deadly form of brain cancer globally. It aggressively invades brain tissue and causes rapid onset of neurological symptoms. This invasion includes fostering a highly vascularized microenvironment and intricate interactions between tumor and non-tumor cells within the brain which promotes its growth and survival despite current treatments... read post here.

Pancreatic cancer is a terrible disease. The most common form, pancreatic ductal adenocarcinoma (PDAC), has a grim prognosis and the efficacy of existing and experimental treatments leaves much to be desired. Toward addressing the need for new therapies, we are announcing... read post here.

Endometriosis is a painful inflammatory disease that affects millions of women worldwide. The current treatment landscape, which includes over-the-counter pain medication, hormone therapy, and hysterectomy, does not offer sustainable solutions for the vast majority of patients. Therefore, there is a serious unmet clinical need for disease-modifying therapies that provide long-term symptom relief.[1] To that end, we are announcing a collaboration with Adynxx, a clinical-stage biotech, to develop a non-hormonal drug therapy with the potential to address the underlying mechanisms of endometriosis and significantly improve upon the standard of care... read post here.

twoXAR Co-Founder, Andrew M. Radin, discusses Recent IP and Business Trends in Advanced Drug Discovery Technology panel with Ichiro Nakatomi, S. Roy Kimura, Patrick Reid, Rob Garbaccio.

twoXAR Co-Founder, Andrew M. Radin, discusses the applications of AI in Drug Discovery.

twoXAR CEO, Andrew A. Radin, discusses the applications of AI in Drug Discovery.

Meet twoXAR and other technology-driven life science and healthcare companies for networking, recruiting, and more.

twoXAR Co-Founder, Andrew M. Radin, discusses artificial intelligence in drug discovery.

twoXAR CEO, Andrew A. Radin, discusses artificial intelligence in drug discovery and how it's impacting the discovery of novel ophthalmology therapeutics.

twoXAR CEO, Andrew A. Radin, speaks about the Applications of AI in Drug Discovery

twoXAR CEO, Andrew A. Radin, speaks with Harry Glorikian of the Moneyball Medicine Podcast.

twoXAR CEO, Andrew A. Radin, is joined by GSK's John Baldoni & Nimbus's Mark Ashwell.

twoXAR CEO, Andrew A. Radin, presents What if new medications could be found in minutes instead of years?

twoXAR CEO, Andrew A. Radin, is joined by Jeff Kindler & Vijay Pande.